
Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Advertisement
Articles by Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1

Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
2
Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice
3
Health Equity & Access Weekly Roundup: November 20, 2026
4
Low CRC Incidence Found After Endoscopic Mucosal Resection
5